Eli Lilly's diabetes drug Mounjaro gets approval for a new use

Live updates

1. 14d ago

   FDA expands Mounjaro approval to reduce major cardiovascular events

   The FDA approved Eli Lilly's tirzepatide, marketed as Mounjaro, to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for such events. This new indication allows the GLP-1 medication to be used specifically to reduce risks including strokes. The approval expands the drug's utility beyond glucose management to include the prevention of heart disease and related cardiovascular complications in this patient population.

   Why it matters

   Mounjaro belongs to a class of GLP-1 receptor agonists used for diabetes and weight management. Reducing major adverse cardiovascular events is a critical metric for treating high-risk type 2 diabetes patients. This expansion increases the clinical applications for Eli Lilly's medication.

   What is confirmed

   • The FDA approved Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for CV events.
   • Mounjaro reduced major cardiovascular events, including strokes.

   What to watch next

   • Clinical data regarding the specific percentage of risk reduction for strokes
   • Updates on insurance coverage for the new cardiovascular indication
   Sources used for this update (6)

   1. www.rttnews.com — Biotech & Pharma News, Stocks, FDA Decision, Clinical Trials - RTTNews
   2. www.indystar.com — Eli Lilly's diabetes drug Mounjaro gets approval for a new use
   3. www.wbay.com — FDA approves new use for diabetes drug Mounjaro
   4. www.thecardiologyadvisor.com — Mounjaro Approved to Reduce MACE Risk in Adults With T2DM
   5. finance.yahoo.com — Novo Nordisk A/S (NVO)
   6. finance.yahoo.com — Eli Lilly and Company (LLY.BA)
   confidence 100%
2. 16d ago

   FDA approves Mounjaro to reduce cardiovascular risk in type 2 diabetes adults

   The US Food and Drug Administration approved Eli Lilly's diabetes medication Mounjaro, known as tirzepatide, for a new indication to reduce cardiovascular risk. This approval specifically targets adults living with type 2 diabetes. The drug is now authorized to lower the risk of heart disease and related heart events in this patient population.

   Why it matters

   Mounjaro was previously used primarily for blood sugar management in diabetes patients. Expanding the drug's approved use to include heart health increases its clinical utility for high-risk patients. This move follows a trend of metabolic drugs demonstrating benefits beyond glucose control.

   What is confirmed

   • The US FDA approved Mounjaro to reduce cardiovascular risk.
   • Mounjaro is the brand name for the drug tirzepatide.
   • The approval applies to adults with type 2 diabetes.

   What to watch next

   • Insurance coverage updates for the new cardiovascular indication
   • Clinical data on the specific percentage of risk reduction
   Sources used for this update (6)

   1. Reuters — US FDA approves Lilly's Mounjaro to reduce cardiovascular risk
   2. Bloomberg.com — Lilly Diabetes Shot Mounjaro Wins US Approval for Heart Disease
   3. Eli Lilly and Company — FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
   4. USA Today — Eli Lilly's diabetes drug Mounjaro gets approval for a new use
   5. Time Magazine — Mounjaro Is Now Approved to Lower the Risk of Heart Events
   6. mynews13.com — Downtown Orlando’s The Canopy project gets final approval
   confidence 100%